Table 3 HIV
From: Impact of HIV infection on consolidative radiotherapy for non-Hodgkin diffuse large B-cell lymphoma
Number (n) | (%) | |
|---|---|---|
HAART use | ||
No use | 2 | 7.1 |
Starting at lymphoma diagnosis | 5 | 17.9 |
Long-term users | 20 | 71.4 |
No information | 1 | 3.6 |
NRTI in current scheme | ||
Yes | 4 | 14.8 |
No | 23 | 85.2 |
NNRTI | ||
Yes | 17 | 63.0 |
No | 10 | 37.0 |
Protease inhibitors | ||
Yes | 15 | 55.6 |
No | 12 | 44.4 |
Integrase inhibitors | ||
Yes | 5 | 18.5 |
No | 22 | 81.5 |
Fusion inhibitors | ||
Yes | 0 | 0 |
No | 27 | 100 |
CCCR5 antagonists | ||
Yes | 0 | 0 |
No | 27 | 100 |